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Abstract
Background: Previously reported results of a prospective, randomized placebo-controlled study showed that
the pollen extract (Cernilton) significantly improved total symptoms, pain, and quality of life in patients with
inflammatory prostatitis/chronic pelvic pain syndrome (CP/CPPS) without severe side effects. A phytotherapeutic
agent, Eviprostat, is reportedly effective in a rat model of nonbacterial prostatitis. The aim of the present study
was to compare the efficacy and safety of Eviprostat to that of the pollen extract in the management of CP/CPPS.
Methods: The patients with category III CP/CPPS were randomized to receive either oral capsules of Eviprostat
(two capsules, q 8 h) or the pollen extract (two capsules, q 8 h) for 8 weeks. The primary endpoint of the study
was symptomatic improvement in the NIH Chronic Prostatitis Symptom Index (NIH-CPSI). Participants were evaluated
using the NIH-CPSI and the International Prostate Symptom Score (IPSS) at baseline and after 4 and 8 weeks.
Results: In the intention-to-treat analysis, 100 men were randomly allocated to Eviprostat (n = 50) or the pollen extract
(n = 50). Response (defined as a decrease in the NIH-CPSI total score by at least 25 %) in the Eviprostat group and the
pollen extract group was 88.2 and 78.1 %, respectively. There was no significant difference in the total, pain, urinary,
and quality of life (QOL) scores of the NIH-CPSI between the two groups at 8 weeks. This was also the case with the
total, voiding, and storage symptoms of the IPSS. There were no severe adverse events observed in any patients in
this study.
Conclusion: Both the pollen extract and Eviprostat significantly reduced the symptoms of category III CP/CPPS without
any adverse events. Eviprostat may have an identical effect on category III CP/CPPS compared the pollen extract.
Trial registration: The study was registered with the University Hospital Medical Information Network Clinical Trials
Registry in Japan (UMIN000019618); registration date: 3 November 2015.
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Background
Prostatitis is a relatively common urological disease that
occurs in adult men [1]. The U.S. National Institutes of
Health (NIH) Advisory Committees divided prostatitis
into four categories [2, 3]. Of these, the incidence of
category III disease, chronic prostatitis/chronic pelvic
pain syndrome (CP/CPPS) is believed to be very high
[1]. Category III prostatitis is subdivided into the inflam-
matory type (IIIA; similar to nonbacterial CP) and non-
inflammatory type (IIIB; similar to prostatodynia) based
on the presence (IIIA) or absence (IIIB) of leukocytes in
prostatic secretions or seminal plasma [2, 3].
While the cause of CP/CPPS is presently unknown, it
is a disease that has many clinical issues because it is
often resistant to various treatments [4–6]. To date, CP/
CPPS has been treated using alpha-blockers, antibacterial
agents, anti-inflammatory agents, and phytotherapeutic
agents with varying outcomes [4–12]. Phytotherapeutic
agents that have been used include pollen extract, quer-
cetin, and saw palmetto. Several years ago, Wagenlehner
FM et al. announced the results of a prospective, random-
ized placebo-controlled study, which indicated that the
pollen extract (Cernilton) significantly improved the total
symptoms, pain, and quality of life in patients with
inflammatory prostatitis/chronic pelvic pain syndrome
(CP/CPPS) without any severe adverse effects [6].
Eviprostat is a phytotherapeutic agent widely used in
the treatment of prostatic hypertrophy and has been
used in Japan and Germany for more than 40 years [13–
15]. Eviprostat consists of five components: four are ex-
tracted from the umbellate wintergreen Chimaphila
umbellata, the aspen Populus tremula, the small pasque
flower Pulsatilla pratensis, and the field horsetail Equi-
setum arvense, and the fifth is germ oil from wheat
(Tritium aestivum) [13–15].
Oka et al. administered Eviprostat treatment in a rat
model of nonbacterial prostatitis and reported that oxi-
dative stress and proinflammatory cytokines in the en-
larged prostate were considerably suppressed, and that
Eviprostat may be useful in the clinical treatment of CP/
CPPS [13–15]. Here we conducted a randomized pro-
spective study to determine the effectiveness and safety




This double-blind, prospective, randomized and multi-
centre clinical phase 3 study was conducted in 8 Japan
urologic centers to ascertain the safety and efficacy of
8-weeks Eviprostat in men diagnosed with inflamma-
tory CP/CPPS.
The design of the study was in accordance with the
guidelines for clinical trials in CP/CPPS described by
the NIH Chronic Prostatitis Collaborative Research
Network [16].
Inclusion criteria were [1] men between 20 and 80 year
of age with symptoms of pelvic pain for 3 months or
more before study [2]. Patients with a total National
Institutes of Health Chronic Prostatitis Symptom Index
(NIH-CPSI) score ≥15 point [3]. Patients diagnosed with
NIH category IIIA and IIIB using the PPMT (pre- and
post-massage test) . Category IIIA refers to the presence
of white blood cells (WBC) after a prostate massage
urine specimen (VB3) (WBC in VB3 > 10/hps). Category
IIIB refers to patients with pelvic pain with no evidence
of inflammation on VB3.
Exclusion criteria were [1] documented urinary tract
infection (midstream urine culture with at least 100,000
colony-forming units per milliliter), [2] history of ureth-
ritis, epididymitis or sexually transmitted disease (STD)
[3] history of prostate surgery [4] history of urogenital
cancer [5] treatment with phytotherapeutic agents, a-
blocker agents, or antimicrobials. [6] residual urine
volume >50 ml resulting from bladder outlet ob-
struction (BOO).
The study protocol was approved by the ethical com-
mittee of Hirosaki University School of Medicine, Ao-
mori, Japan. Written informed consent was obtained
from all patients to participation in this study. This
study was registered with the Hirosaki University Hos-
pital Clinical Trials Registry in Japan (2009-013) on 24
May 2009 and was registered with the University Hos-
pital Medical Information Network Clinical Trials Regis-
try in Japan (UMIN000019618) on 3 November 2015.
Study procedure
We included in our study patients with urinary symp-
toms who met our inclusion criteria from among pa-
tients who had been diagnosed with clinically chronic
prostatitis in medical interviews. The significance, objec-
tives, and methods of this clinical study were fully
explained to the patients, and their voluntary written in-
formed consent was obtained. The patients’ subjective
symptoms were evaluated using NIH-CPSI (Japanese
version) and International Prostate Symptom Score
(IPSS) (Japanese version) [17, 18].
We checked patients 1 week after initiating drug therapy
to ascertain whether they met the inclusion criteria. Patients
were then allocated to receive either Eviprostat [two cap-
sules q8h, with the active substance consisting of the um-
bellate wintergreen Chimaphila umbellate extract 0.5 mg,
the aspen Populus tremula extract 0.5 mg, the small pasque
flower Pulsatilla pratensis extract 0.5 mg, the field horsetail
Equisetum arvense extract 1.5 mg and germ oil from wheat
(Tritium aestivum) 15.0 mg.] or pollen extract (two cap-
sules q8h, with the active substance consisting of 60 mg
Cernitin T60 and 3 mg Cernitin GBX) The allocation
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manager randomly determined which of the 2 drugs would
be administered to each patient. Cards detailing the drug to
be used were sealed in numbered envelopes and distributed
to patients from the smallest number to the largest. The
drug to be used was decided on the basis of the card.
Statistical analysis
We used the SPSS 21.0 software package (SPSS, Chicago,
IL) for statistical analyses. Intergroup differences were an-
alyzed by the Student’s t-test. Intragroup differences were
analyzed by a paired t-test. A value of P < 0.05 was consid-
ered statistically significant.
Results
We randomized 100 patients diagnosed Category III A/
III B prostatitis. 80 patients completed 12 weeks of follow-
up and had primary and secondary outcomes ascertained.
Flow chart of this study was presented in Fig. 1. In Evipro-
stat group, 7 patients were lost to follow-up and 2 patients
declined to participate the study. In pollen extract group,
8 patients were lost to follow up and 3 patients declined
to participate the study.
In Eviprostat group, there were 26 category IIIA pa-
tients and 15 category IIIB patients. In pollen extract
group, there were 20 category IIIA patients and 19 cat-
egory IIIB patients. There were no differences from
baseline in the number of leukocytes in the prostatic se-
cretion between the two groups.
The baseline characteristics of each study group are
presented in Table 1. In the Quality of Life (QOL) do-
main of NIH-CPSI, there were significant differences be-
tween two groups. (p = 0.014) Except for QOL domain,
there were no significant differences between the two
groups at the start of this study.
Response (defined as a decrease in the NIH-CPSI total
score by at least 25 %) in the Eviprostat group and the
pollen extract group at 4 week was 68.3 and 61.5 %, re-
spectively. Response in the Eviprostat group and the
pollen extract group was 88.2 and 78.1 %, respectively.
There were no severe adverse events observed in any pa-
tients in this study (Table 2). There was no significant dif-
ference in the total, pain, urinary, and the QOL scores of
the NIH-CPSI between the two groups at 4 weeks and
8 weeks (Fig. 2). There were no significant differences
about the total, voiding, and storage symptoms of the IPSS
between two groups (Fig. 3). There were no severe adverse
events observed in any patients in this study.
Discussion
Antibiotics administration is the standard treatment for
chronic bacterial prostatitis [19], however, the standard
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Fig. 1 Flow chart of this study
Table 1 Patients background
Eviprostat Pollen extract p value
Number 41 39 n.s.
Age 50.1 ± 13.7 53.0 ± 14.6 n.s.
CategoryIIIA/IIIB 26/15 20/19 n.s.
Duration of current
symptoms (months)
8.2 ± 10.6 9.5 ± 11.2 n.s.
IPSS 10.8 ± 7.5 11.6 ± 7.3 n.s.
NIH-CPSI
Total score 22.3 ± 4.7 20.3 ± 5.8 n.s.
Pain domain 9.4 ± 4.2 9.2 ± 4.0 n.s.
Urinary domain 4.6 ± 2.8 3.8 ± 2.7 n.s.
QoL domain 8.3 ± 1.6 7.3 ± 2.0 0.014
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To date, various treatments for CP/CPPS have been re-
ported, including α-blockers, antibiotics, anti-inflammatory
agents, phytotherapeutics, and various other modal-
ities [4–12]. However it is believed that these treat-
ments have little effect on major symptoms, such as
pain and urinary disturbance, experienced in CP/CPPS
that reduce the QOL [21].
In general, patients with CP/CPPS undergo long-
term treatment, and therefore, phytotherapeutics such
as pollen extract, quercetin, Saw palmetto, or terpenes
may be useful because they have few side effects [5].
However, there is no scientific evidence supporting these
agents, and only few prospective controlled clinical trials
have been conducted.
Since a long time, Cernilton has been used for the treat-
ment of prostatitis [6]. Wagenlehner et al. conducted a
prospective, randomized, double-blind, placebo-controlled
study to study the effect of Cernilton in patients with CP/
CPPS (NIH IIIA). They reported that compared with a
placebo, Certilton improved total symptom, pain, and
QOL without any side effects [6].
Eviprostat is a phytotherapeutic agent commonly used
to treat prostatic hypertrophy in Japan [13–15]. An ex-
periment using nonbacterial prostatitis model suggested
that Evoprostat is potentially effective for the treatment
of CP/CPPS. Oka et al previously reported that by using
a model of non-bacterial prostatitis (NBP) induced in
castrated aging rats by the injection of 17b-estradiol,
they showed that the increased production of oxidati-
vestress marker malondialdehyde (MDA) and the proin-
flammatory cytokines TNF-a, IL-6, and IL-8 in prostate
tissue homogenates from NBP rats. Eviprostat treatment
significantly suppressed oxidative stress and proinflam-
matory cytokines in the NBP rats [13]. Sugimoto et al
reported that chemokines, including CCL2/MCP-1 and
CXCL1/CINC-1, were elevated in the prostate and urine
of NBP rats, and Eviprostat potently suppressed the in-
creases in CCL2/MCP-1 and CXCL1/CINC-1 [14].
The aim of the present study was to compare the
efficacy and safety of Eviprostat to that of the pollen
extract in the management of CP/CPPS.
Fig. 2 Mean change from baseline in the NIH-CPSI total score and in the sub-score after 4 and 8 week of treatment with Cernilton
group or Eviprostat group. a NIH-CPSI total score. b NIH-CPSI pain domain score. c NIH-CPSI urinary domain score. d NIH-CPSI QOL
domain score
Table 2 25% response rates for NIH-CPSI
Eviprostat Pollen extract
4 weeks 8 weeks 4 weeks 8 weeks
Total variation -8.9 -11.1 -7.8 -10.5
Adverse event (%) 1.7 2.3 2.3 4.7
25 % response rates (%) 68.3 88.2 61.5 78.1
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In the intention-to-treat analysis, 100 Category III CP/
CPPS patients were randomly allocated to Eviprostat (n =
50) or the pollen extract (n = 50). Response (defined as a
decrease in the NIH-CPSI total score by at least 25 %) in
the Eviprostat group and the pollen extract group was
88.2 and 78.1 %, respectively. There was no significant dif-
ference in the total, pain, urinary, and QOL scores of the
NIH-CPSI between the two groups at 8 weeks.
This study has several limitations. Study samples were
very small, it is necessary to examine the therapeutic ef-
fects of Eviprostat with a placebo control and this study
was conducted in only Japanese populations.
In the present study, we conducted a prospective, ran-
domized trial to compare the therapeutic effects of Evipro-
stat and Certilton, the standard treatment for CP/CPPS in
Japan, and found that both agents improved CP/CPPS
without any side-effects. We believe that Eviprostat is a
very promising phytotherapeutic agent for the treatment
of CP/CPPS in the future.
Conclusion
Both the pollen extract and Eviprostat significantly re-
duced the symptoms of category III CP/CPPS without any
adverse events. Eviprostat may have an identical effect on
category III CP/CPPS compared the pollen extract.
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